Stockscreener 앱 받기
2.56
1.99%
0.05
시간 외 거래:
2.55
-0.01
-0.39%
전일 마감가:
$2.51
열려 있는:
$2.51
하루 거래량:
33,299
Relative Volume:
0.26
시가총액:
$41.09M
수익:
$6.66M
순이익/손실:
$-25.52M
주가수익비율:
-2.1157
EPS:
-1.21
순현금흐름:
$-28.98M
1주 성능:
-3.76%
1개월 성능:
+14.29%
6개월 성능:
-24.04%
1년 성능:
-51.23%
1일 변동 폭
$2.49
$2.63
1주일 범위
$2.44
$2.67
52주 변동 폭
$2.10
$7.40
Veru Inc Stock (VERU) Company Profile
명칭
Veru Inc
전화
(312) 595-9123
주소
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.56 | 40.29M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Canaccord Genuity | Buy |
| 2024-05-14 | 개시 | B. Riley Securities | Buy |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2023-06-07 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2018-07-03 | 개시 | Maxim Group | Buy |
모두보기
Veru Inc 주식(VERU)의 최신 뉴스
Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Veru : Corporate Presentation, February 2026 - marketscreener.com
VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VERU Should I Buy - Intellectia AI
Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com
VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI
Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI
Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Q1 2026 earnings preview - MSN
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - The Manila Times
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru (VERU) price target increased by 11.11% to 25.50 - MSN
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq
Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative
Biopharma Veru sets Feb. 11 webcast on Q1 2026 results - Stock Titan
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - Yahoo Finance
Published on: 2026-02-01 18:16:35 - baoquankhu1.vn
Wall Street Recap: Is Veru Inc a defensive stockJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Block Trades: Will Veru Inc benefit from AI trends2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
Analyzing Verano (OTCMKTS:VRNOF) & Veru (NASDAQ:VERU) - Defense World
Growth Report: Will Veru Inc benefit from AI trends2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
Veru prices 1.4M shares at $3.00 in underwritten public offering - MSN
Targets Report: Will Veru Inc stock attract ESG investors2025 Market Sentiment & Real-Time Volume Analysis - Bộ Nội Vụ
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
Is Veru Inc. stock a buy in volatile marketsJuly 2025 Final Week & Trade Opportunity Analysis - Улправда
Why Veru Inc. (FMW) stock trades below fair valueTrade Entry Report & Fast Entry High Yield Tips - ulpravda.ru
Veru Inc (VERU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):